 |
|
|
|
|
Investors
Argos Therapeutics is an immunotherapy company developing new treatments for cancer,
infectious, inflammatory and autoimmune diseases, and transplantation rejection. The Company has
generated multiple platform technologies and a diverse pipeline of products based on
its expertise in the biology of dendritic cells – the master switch that turns
the immune system on or off.
To date, the Company has raised approximately $80 million from top-tier life science investors to
support our research and development.
Product Pipeline
If you are interested in discussing investment opportunities with Argos Therapeutics,
please contact us at businessdev@argostherapeutics.com.
|
|
 |
|
